Skip to main content

Table 2 Marker levels in highly active antineutrophil cytoplasmic antibody-associated vasculitis before treatment and remission at 6 months

From: Targeted proteomics reveals promising biomarkers of disease activity and organ involvement in antineutrophil cytoplasmic antibody-associated vasculitis

Marker Highly active (n = 62) Remission (n = 62) p Value AUCa COPb Sensitivity Specificity LR + c
CRP, mg/dl 6.34 (2.14–11.5) 0.06 (0.01–0.16) < 0.0001d 0.93 1.22 82 95 17.0
TIMP1, ng/ml 329 (250–405) 156 (134–175) < 0.0001d 0.93 205 92 89 8.14
LRG1, μg/ml 151 (110–231) 40.1 (29.8–62.0) < 0.0001d 0.9 71.9 89 85 6.11
TNC, ng/ml 144 (97.7–272) 47.0 (37.0–68.3) < 0.0001d 0.88 72.7 90 79 4.31
S100A8/A9, μg/ml 6.4 (4.4–10.3) 2.2 (1.2–3.8) < 0.0001d 0.86 4.1 77 82 4.36
CD93, ng/ml 192 (151–252) 124 (103–164) < 0.0001d 0.78 146 79 69 2.58
TKT, ng/ml 104 (61.8–162) 52.0 (28.9–91.5) < 0.0001d 0.72 115 47 90 4.83
MMP9, ng/ml 909 (447–1623) 566 (330–839) 0.0007d 0.67 897 53 77 2.36
MPO-ANCA,e U/ml 63.5 (27.4–223) 0.8 (0.5–2.2) < 0.0001d 0.96 5.1 98 88 7.83
  1. Abbreviations: ANCA Antineutrophil cytoplasmic antibody, COP Cutoff point, CRP C-reactive protein, LR Likelihood ratio, LRG1 Leucine-rich alpha-2-glycoprotein 1, MMP9 Matrix metalloproteinase 9, MPO Myeloperoxidase, TIMP1 Tissue inhibitor of metalloproteinase 1, TKT Transketolase, TNC Tenascin C
  2. Values are median (IQR)
  3. aAn AUC of 1 indicates perfect discrimination between groups; an AUC of 0.5 indicates no discrimination
  4. bThe maximum sum of sensitivity and specificity
  5. cPositive likelihood ratio at the COP, which equals sensitivity/(1 − specificity)
  6. d p < 0.05 by Wilcoxon signed-rank test
  7. eOnly MPO-ANCA-positive patients (n = 48)